Literature DB >> 18510883

Do statins and/or ACE inhibitors impact risk for or outcome of pneumonia in certain populations?

Janet R Maurer.   

Abstract

Entities:  

Year:  2008        PMID： 18510883     DOI： 10.1007/s11908-008-0035-6

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  6 in total

1.  Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study.

Authors:  Sumit R Majumdar; Finlay A McAlister; Dean T Eurich; Raj S Padwal; Thomas J Marrie
Journal:  BMJ       Date:  2006-10-23

2.  Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes.

Authors:  Ewoudt M W van de Garde; Patrick C Souverein; Eelko Hak; Vera H M Deneer; Jules M M van den Bosch; Hubert G M Leufkens
Journal:  J Hypertens       Date:  2007-01       Impact factor: 4.844

3.  Statin therapy is associated with fewer deaths in patients with bacteraemia.

Authors:  Peter Kruger; Kenneth Fitzsimmons; David Cook; Mark Jones; Graeme Nimmo
Journal:  Intensive Care Med       Date:  2005-11-10       Impact factor: 17.440

4.  Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population.

Authors:  E M W van de Garde; P C Souverein; J M M van den Bosch; V H M Deneer; H G M Leufkens
Journal:  Eur Respir J       Date:  2006-02-02       Impact factor: 16.671

5.  Prior statin therapy is associated with a decreased rate of severe sepsis.

Authors:  Yaniv Almog; Alexander Shefer; Victor Novack; Nimrod Maimon; Leonid Barski; Miruna Eizinger; Michael Friger; Lior Zeller; Abraham Danon
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

6.  The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia.

Authors:  Eric M Mortensen; Marcos I Restrepo; Antonio Anzueto; Jacqueline Pugh
Journal:  BMC Pulm Med       Date:  2005-09-13       Impact factor: 3.317
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.